Taken together, these results reveal that drugs inhibiting intestinal reabsorption of BAs (Asbt inhibitor, IBAT inhibitor) that are on clinical trials for NASH and cholestasis can be evaluated as potential therapeutics to combat HCC. Here, SLC10A2 is linked to metabolic dysfunction-associated steatohepatitis.